The pediatric glucocorticoid toxicity index.

Acne Adverse effects Asthma Body mass index Bone mineral density Clinical outcome assessment Damage Glucocorticoid Growth Hemoglobin A1c Hirsutism Hypertension Infection Juvenile idiopathic arthritis Kawasaki's disease Mood Myopathy Osteonecrosis Sleep Toxicity

Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
10 2022
Historique:
received: 02 05 2022
revised: 21 06 2022
accepted: 08 07 2022
pubmed: 3 8 2022
medline: 9 9 2022
entrez: 2 8 2022
Statut: ppublish

Résumé

To develop a Pediatric glucocorticoid toxicity index (pGTI), a standardized, weighted clinical outcome assessment that measures change in glucocorticoid (GC) toxicity over time. Fourteen physician experts from 7 subspecialties participated. The physician experts represented multiple subspecialties in which GCs play a major role in the treatment of inflammatory disease: nephrology, rheumatology, oncology, endocrinology, genetics, psychiatry, and maternal-fetal medicine. Nine investigators were from Canada, Europe, or New Zealand, and 5 were from the United States. Group consensus methods and multi-criteria decision analysis were used. The pGTI is an aggregate assessment of GC toxicities that are common, important, and dynamic. These toxicities are organized into health domains graded as minor, moderate, or major and are weighted according to severity. The relative weights were derived by group consensus and multi-criteria decision analysis using the 1000Minds One hundred and seven (107) toxicity items were included in the pGTI and thirty-two (32) in the Damage Checklist. To assess the degree to which the pGTI corresponds to expert clinical judgement, the investigators ranked 15 cases by clinical judgement from highest to lowest GC toxicity. Expert rankings were then compared to case ranking by the pGTI, yielding excellent agreement (weighted kappa 0.86). The pGTI was migrated to a digital environment following its development and initial validation. The digital platform is designed to ensure ease-of-use in the clinic, rigor in application, and accuracy of scoring. Clinic staff enter vital signs, laboratory results, and medication changes relevant to pGTI scoring. Clinicians record findings for GC myopathy, skin toxicity, mood dysfunction, and infection. The pGTI algorithms then apply the weights to these raw data and calculate scores. Embedded logic accounts for the impact of age- and sex-related reference ranges on several health domains: blood pressure, lipid metabolism, and bone mineral density. Other algorithms account for anticipated changes in the height Z-scores used in the growth domain, thereby addressing a concern unique to GC toxicity in children. The Damage Checklist ensures comprehensive measurement of GC toxicity but does not contribute to pGTI scoring, because the scored domains emphasize manifestations of GC toxicity that are likely to change over the course of a trial. We describe the development and initial evaluation of a weighted, composite toxicity index for the assessment of morbidity related to GC use in children and adolescents. Developing the pGTI digital platform was essential for performing the nuanced calculations necessary to ensure rigor, accuracy, and ease-of-use in both clinic and research settings.

Identifiants

pubmed: 35917759
pii: S0049-0172(22)00119-6
doi: 10.1016/j.semarthrit.2022.152068
pii:
doi:

Substances chimiques

Glucocorticoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

152068

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest relevant to this article to disclose.

Auteurs

Paul Brogan (P)

Great Ormond Street Hospital NHS Foundation Trust, University College London Great Ormond Street Institute of Child Health, London UK.

Ray Naden (R)

McMasterUniversity, Hamilton, Ontario, Canada.

Stacy P Ardoin (SP)

Ohio State University; Columbus, OH, USA.

Jennifer C Cooper (JC)

University of Colorado Anschutz Medical Alifornia, San Francisco, CA, USA.

Fabrizio De Benedetti (F)

Hopital Bambino Gesu, Rome, Italy.

Jean-Francois Dicaire (JF)

Pinnacle, Montreal, Quebec, Canada.

Despina Eleftheriou (D)

Great Ormond Street Hospital NHS Foundation Trust, University College London Great Ormond Street Institute of Child Health, London UK.

Brian Feldman (B)

Hospital for Sick Children, Toronto, Ontario, Canada.

Jon Goldin (J)

Great Ormond Street Hospital NHS Foundation Trust, University College London Great Ormond Street Institute of Child Health, London UK.

Seth E Karol (SE)

St. Jude Children's Research Hospital, Memphis, TN, USA.

Fiona Price-Kuehne (F)

Cambridge University Hospitals, Cambridge, UK.

David Skuse (D)

Great Ormond Street Hospital NHS Foundation Trust, University College London Great Ormond Street Institute of Child Health, London UK.

Constantine A Stratakis (CA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.

Nicholas Webb (N)

Royal Manchester Children's Hospital, Manchester, UK; Rheumatology Clinic, Bulfinch 165, Massachusetts General Hospital, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

John H Stone (JH)

Great Ormond Street Hospital NHS Foundation Trust, University College London Great Ormond Street Institute of Child Health, London UK. Electronic address: jhstone@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH